Jan Sadones

998 total citations
17 papers, 822 citations indexed

About

Jan Sadones is a scholar working on Genetics, Cancer Research and Neurology. According to data from OpenAlex, Jan Sadones has authored 17 papers receiving a total of 822 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 8 papers in Cancer Research and 5 papers in Neurology. Recurrent topics in Jan Sadones's work include Glioma Diagnosis and Treatment (15 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Brain Metastases and Treatment (4 papers). Jan Sadones is often cited by papers focused on Glioma Diagnosis and Treatment (15 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Brain Metastases and Treatment (4 papers). Jan Sadones collaborates with scholars based in Belgium, Netherlands and Finland. Jan Sadones's co-authors include Jacques De Grève, Bart Neyns, Alex Michotte, C. Chaskis, Erik Teugels, Pieter In 'T Veld, Lionel D’Hondt, Ijeoma Adaku Umelo, Peter Kronenberger and Shasha Lv and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

Jan Sadones

17 papers receiving 807 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan Sadones Belgium 12 437 428 348 165 151 17 822
Sandra Boots‐Sprenger Netherlands 11 425 1.0× 511 1.2× 324 0.9× 157 1.0× 129 0.9× 12 829
Kerstin Kaulich Germany 14 296 0.7× 517 1.2× 277 0.8× 121 0.7× 159 1.1× 20 790
Takanori Kamiryo Japan 6 341 0.8× 478 1.1× 230 0.7× 141 0.9× 200 1.3× 7 752
Shoji Shiraishi Japan 10 396 0.9× 601 1.4× 260 0.7× 179 1.1× 235 1.6× 10 947
I‐Mei Siu United States 16 494 1.1× 292 0.7× 190 0.5× 121 0.7× 160 1.1× 22 823
Koji Oka Japan 9 310 0.7× 351 0.8× 195 0.6× 138 0.8× 227 1.5× 23 727
David Shih United States 16 668 1.5× 533 1.2× 230 0.7× 113 0.7× 155 1.0× 35 1.1k
T. Mikkelsen United States 11 270 0.6× 515 1.2× 205 0.6× 220 1.3× 134 0.9× 21 731
Kenneth Aldape United States 9 286 0.7× 322 0.8× 149 0.4× 135 0.8× 120 0.8× 21 648
Michael Badruddoja United States 8 238 0.5× 387 0.9× 160 0.5× 152 0.9× 167 1.1× 20 681

Countries citing papers authored by Jan Sadones

Since Specialization
Citations

This map shows the geographic impact of Jan Sadones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Sadones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Sadones more than expected).

Fields of papers citing papers by Jan Sadones

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Sadones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Sadones. The network helps show where Jan Sadones may publish in the future.

Co-authorship network of co-authors of Jan Sadones

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Sadones. A scholar is included among the top collaborators of Jan Sadones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Sadones. Jan Sadones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Kramer, Gertjan, Katrijn Verhaeghen, Geert Stangé, et al.. (2015). Potential of UCHL1 as biomarker for destruction of pancreatic beta cells. Journal of Proteomics. 117. 156–167. 21 indexed citations
2.
Chen, Gang, Ijeoma Adaku Umelo, Shasha Lv, et al.. (2013). miR-146a Inhibits Cell Growth, Cell Migration and Induces Apoptosis in Non-Small Cell Lung Cancer Cells. PLoS ONE. 8(3). e60317–e60317. 238 indexed citations
3.
Teugels, Erik, Jan Sadones, Sylvia De Brakeleer, et al.. (2012). Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. International Journal of Oncology. 41(3). 1029–1035. 56 indexed citations
4.
Teugels, Erik, Jan Sadones, Erik Quartier, et al.. (2011). Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.. PubMed. 31(12). 4457–63. 31 indexed citations
5.
Neyns, Bart, Jan Sadones, C. Chaskis, et al.. (2010). Phase II study of sunitinib malate in patients with recurrent high-grade glioma. Journal of Neuro-Oncology. 103(3). 491–501. 113 indexed citations
6.
Neyns, Bart, Jan Sadones, E. Joosens, et al.. (2009). Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Annals of Oncology. 20(9). 1596–1603. 182 indexed citations
7.
Michotte, Alex, C. Chaskis, Jan Sadones, Pieter In 'T Veld, & Bart Neyns. (2009). Primary leptomeningeal anaplastic oligodendroglioma with a 1p36–19q13 deletion: Report of a unique case successfully treated with Temozolomide. Journal of the Neurological Sciences. 287(1-2). 267–270. 23 indexed citations
8.
Chaskis, C., Bart Neyns, M Dujardin, et al.. (2009). Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma. Surgical Neurology. 72(5). 518–518. 1 indexed citations
9.
Neyns, Bart, C. Chaskis, M Dujardin, et al.. (2009). Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma. Journal of Clinical Oncology. 27(15_suppl). 2038–2038. 11 indexed citations
10.
Neyns, Bart, Jan Sadones, E. Joosens, et al.. (2008). A Multicenter Stratified Phase Ii Study of Cetuximab for the Treatment of Patients With Recurrent High-grade Glioma. Neuro-Oncology. 10(6). 1067. 8 indexed citations
11.
Sadones, Jan, Alex Michotte, Pieter In 'T Veld, et al.. (2008). MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. European Journal of Cancer. 45(1). 146–153. 45 indexed citations
12.
Neyns, Bart, C. Chaskis, E. Joosens, et al.. (2008). A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma. Cancer Investigation. 26(3). 269–277. 35 indexed citations
13.
Neyns, Bart, Jan Sadones, E. Joosens, et al.. (2008). A multicenter stratified phase II study of cetuximab for the treatment of patients with recurrent high-grade glioma. Journal of Clinical Oncology. 26(15_suppl). 2017–2017. 7 indexed citations
14.
Chaskis, C., Jan Sadones, Alex Michotte, et al.. (2008). A phase II trial of sunitinib in patients with recurrent high-grade glioma. Journal of Clinical Oncology. 26(15_suppl). 13001–13001. 12 indexed citations
15.
Sadones, Jan, C. Chaskis, E. Joosens, et al.. (2006). A stratified phase II study of cetuximab for the treatment of recurrent glioblastoma multiforme: Preliminary results. Journal of Clinical Oncology. 24(18_suppl). 1558–1558. 12 indexed citations
16.
Neyns, Bart, Jan Sadones, C. Chaskis, et al.. (2005). The role of chemotherapy in the treatment of low-grade glioma. A review of the literature.. PubMed. 105(3). 137–43. 6 indexed citations
17.
Michotte, Alex, Bart Neyns, C. Chaskis, Jan Sadones, & Pieter In 'T Veld. (2004). Neuropathological and molecular aspects of low-grade and high-grade gliomas.. PubMed. 104(4). 148–53. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sandra Boots‐Sprenger Breakdown of academic impact, for papers by Kerstin Kaulich Breakdown of academic impact, for papers by Takanori Kamiryo Breakdown of academic impact, for papers by Shoji Shiraishi Breakdown of academic impact, for papers by I‐Mei Siu Breakdown of academic impact, for papers by Koji Oka Breakdown of academic impact, for papers by David Shih Breakdown of academic impact, for papers by T. Mikkelsen Breakdown of academic impact, for papers by Kenneth Aldape Breakdown of academic impact, for papers by Michael Badruddoja
Rankless by CCL
2026